CRBP (Corbus Pharmaceuticals Holdings) Operating Margin %: 0.00% (As of Mar. 2026)


CRBP Corbus Pharmaceuticals Holdings Inc CRBP
32 GF Score
Price $8.25
! 1 Warning Sign
View Full Analysis

What is Corbus Pharmaceuticals Holdings Operating Margin %?

Corbus Pharmaceuticals Holdings CRBP +0.92% 32 Operating Margin % is 0.00% as of Mar. 2026. GuruFocus rates CRBP with a GF Score™ of 32/100. The stock has 1 warning sign investors should review. Among 945 Biotechnology companies, Corbus Pharmaceuticals Holdings ranks worse than 105820% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Corbus Pharmaceuticals Holdings's Operating Income for the three months ended in Mar. 2026 was $-24.30 Mil. Corbus Pharmaceuticals Holdings's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Corbus Pharmaceuticals Holdings's Operating Margin % for the quarter that ended in Mar. 2026 was 0.00%.

The historical rank and industry rank for Corbus Pharmaceuticals Holdings's Operating Margin % or its related term are showing as below:


CRBP's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -86.89
* Ranked among companies with meaningful Operating Margin % only.

Corbus Pharmaceuticals Holdings's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Corbus Pharmaceuticals Holdings's Operating Income for the three months ended in Mar. 2026 was $-24.30 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was $-89.84 Mil.


Corbus Pharmaceuticals Holdings  (NAS:CRBP) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Corbus Pharmaceuticals Holdings Operating Margin % Related Terms


Corbus Pharmaceuticals Holdings Operating Margin % Historical Data

* Premium members only.

The historical data trend for Corbus Pharmaceuticals Holdings's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corbus Pharmaceuticals Holdings Operating Margin % Chart

Corbus Pharmaceuticals Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6,347.96 0.00 0.00 0.00 0.00

Corbus Pharmaceuticals Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CRBP vs AGEN, HURA, SLNCF: Operating Margin % Comparison

For the Biotechnology subindustry, Corbus Pharmaceuticals Holdings's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Corbus Pharmaceuticals Holdings Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corbus Pharmaceuticals Holdings's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Corbus Pharmaceuticals Holdings's Operating Margin % falls into.


CRBP
32GF Score
Corbus Pharmaceuticals Holdings Inc CRBP
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Corbus Pharmaceuticals Holdings Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Corbus Pharmaceuticals Holdings's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=-85.31 / 0
= %

Corbus Pharmaceuticals Holdings's Operating Margin % for the quarter that ended in Mar. 2026 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=-24.304 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of 0.00% mean?
Corbus Pharmaceuticals Holdings (CRBP) has a Operating Margin % of 0.00% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Corbus Pharmaceuticals Holdings and its competitors. According to the industry distribution chart, Corbus Pharmaceuticals Holdings ranks #999999 out of 945 companies in the Biotechnology industry.
Is Corbus Pharmaceuticals Holdings' Operating Margin % too high?
Corbus Pharmaceuticals Holdings' current Operating Margin % is 0.00%. Based on the distribution chart, Corbus Pharmaceuticals Holdings ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Corbus Pharmaceuticals Holdings has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Corbus Pharmaceuticals Holdings' Operating Margin % compare to AGEN and HURA?
According to the Biotechnology industry distribution chart, Corbus Pharmaceuticals Holdings ranks #999999 out of 945 companies for Operating Margin %. This places Corbus Pharmaceuticals Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Corbus Pharmaceuticals Holdings and its competitors. Corbus Pharmaceuticals Holdings's current Operating Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corbus Pharmaceuticals Holdings stock overvalued right now?
Corbus Pharmaceuticals Holdings (CRBP) has a current Operating Margin % of 0.00%. The current Operating Margin % is 0.00%. Corbus Pharmaceuticals Holdings' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Corbus Pharmaceuticals Holdings (CRBP), the current Operating Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Corbus Pharmaceuticals Holdings Business Description

Other Exchanges 0SZI:UK3371:Germany
Address 500 River Ridge Drive, Norwood, MA, USA, 02062
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
32GF Score

Get the complete analysis for CRBP

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.25
Price